BridgeBio Pharma (BBIO) Non-Current Assets (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Non-Current Assets data on file, last reported at $129.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 30.46% year-over-year to $129.7 million; the trailing twelve-month figure through Mar 2026 stood at $594.7 million (down 24.11% YoY), and the FY2025 full-year result was $138.3 million, down 30.39% from the prior year.
• Non-Current Assets fell to $129.7 million in Q1 2026, from $138.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $220.4 million in Q3 2024 to a low of $65.9 million in Q1 2024.
• A 5-year average of $121.9 million and a median of $96.9 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets tumbled 47.0% in 2022 and soared 227.3% in 2024, its largest moves.
• Tracing BBIO's Non-Current Assets over 5 years: stood at $74.2 million in 2022, then fell by 7.27% to $68.8 million in 2023, then soared by 188.78% to $198.6 million in 2024, then tumbled by 30.39% to $138.3 million in 2025, then retreated by 6.22% to $129.7 million in 2026.
• Business Quant data shows BBIO's Non-Current Assets at $129.7 million in Q1 2026, $138.3 million in Q4 2025, and $158.9 million in Q3 2025.